News & Events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer
8 March 2023
Molecure Appoints Dr. Samson Fung, Chief Medical Officer to its Management Board as it Continues to Focus on Successfully Progressing its Expanded Clinical Portfolio Copy
23 January 2023
Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022
5 December 2022
Molecure to begin clinical development of novel dual arginase inhibitor OATD-02 for the treatment of cancer after gaining permission to conduct first clinical trial in Poland
28 November 2022